Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3343094

CC1(C)CCC(NCCOc2ccc(-c3cccc(-c4ncc[nH]4)c3)cc2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
VCP P55072 10/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
MAPK14 Q16539 1/20 0.36
SMO Q99835 1/20 0.36
HTR5A P47898 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL16194992 0.93 CYP1A2 (0.46) ALDH1A1KDM4ETDP1CYP1A2CYP3A4
SCHEMBL12651500 0.92 CYP1A2 (0.46) ALDH1A1KDM4ETDP1CYP1A2CYP3A4
Trifluoroacetic Acid SCHEMBL3340019 0.87 SLC2A1 (0.41) VCPMEN1KMT2AHDAC1MAPK14
SCHEMBL12651501 0.84 CYP1A2 (0.54) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL3346088 0.83 RAD52 (0.40) ALDH1A1KDM4EHTR5A
Trifluoroacetic Acid SCHEMBL3340913 0.82 ALDH1A1 (0.44) ALDH1A1KDM4ETDP1CYP1A2CYP2D6
Trifluoroacetic Acid SCHEMBL3340376 0.82 ALDH1A1 (0.47) ALDH1A1KDM4ETDP1RARBRARG
Trifluoroacetic Acid SCHEMBL3042666 0.81 ALDH1A1 (0.42) ALDH1A1KDM4ETDP1CYP1A2CYP2D6
Trifluoroacetic Acid SCHEMBL3338284 0.80 DPP4 (0.46) ALDH1A1KDM4ETDP1CYP1A2CYP3A4
SCHEMBL1789424 0.78 ALDH1A1 (0.50) ALDH1A1KDM4ETDP1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 ALDH1A1 4254/4885KDM4E 2806/4885TDP1 4830/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 ALDH1A1 3500/4885KDM4E 3829/4885TDP1 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.